13F Holdings
中文EN

USNA USANA HEALTH SCIENCES INC

Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 896264 · Fiscal year ends 01/03

Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.8%
TTM net income YoY-224.8%
TTM EPS YoY-226.7%
Revenue 3-yr CAGR-0.8%
Net income 3-yr CAGR—

Margins

Gross margin77.3%
Operating margin-0.4%
Net margin-2.3%
FCF margin3.3%
EBITDA margin3.2%

Returns

ROE-4.0%
ROA-3.0%
ROIC (approx.)-0.8%
Asset turnover1.26x

Leverage & solvency

Liabilities / assets19.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-9.35x

Cash quality & payout

Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252026-01-03FY20232024-12-28FY20232023-12-30FY20222022-12-31FY20222022-01-01
Income statement
Revenue$925.26M$854.50M$921.01M$998.60M$1.19B
Cost of revenue$200.85M$161.21M$176.69M$193.89M$217.90M
Gross profit$724.40M$693.29M$744.32M$804.71M$968.57M
R&D expense$10.69M$11.57M$11.45M$11.56M$11.11M
SG&A expense$337.37M$263.27M$256.99M$262.30M$279.11M
Operating income$37.43M$66.32M$93.07M$107.61M$170.19M
Interest expense$842,000$281,000$262,000$192,000$57,000
Pretax income$41.53M$76.35M$102.45M$108.62M$170.64M
Income tax$30.05M$34.29M$38.66M$39.27M$54.14M
Net income$10.76M$42.03M$63.79M$69.35M$116.50M
EBITDA$69.99M$80.86M$105.77M$121.01M$183.23M
EPS (basic)0.582.203.313.605.78
EPS (diluted)0.582.193.303.595.73
Weighted avg. shares (diluted)18.57M19.16M19.34M19.31M20.34M
Balance sheet
Cash & equivalents$158.38M$181.77M$330.42M$288.42M$239.83M
Receivables$4.29M————
Inventory$102.61M$69.73M$61.45M$67.09M$98.32M
Current assets$288.40M$279.19M$417.75M$384.38M$365.12M
PP&E, net$94.38M$94.56M$99.81M$97.77M$101.78M
Goodwill$137.96M$144.17M$17.10M$17.37M$17.67M
Intangibles$133.15M$151.82M$29.92M$32.43M$30.44M
Total assets$742.91M$748.19M$632.76M$596.55M$577.74M
Current liabilities$128.56M$139.62M$118.84M$143.83M$160.79M
Total liabilities$156.64M$161.86M$135.56M$162.08M$182.62M
Shareholders' equity$533.10M$532.11M$497.20M$434.47M$395.12M
Shares outstanding18.28M19.06M19.13M19.21M19.39M
Cash flow statement
Operating cash flow$22.35M$60.99M$70.64M$103.90M$121.23M
Capital expenditure$13.82M$10.07M$14.49M$10.40M$12.76M
Free cash flow$8.53M$50.92M$56.15M$93.50M$108.46M
Investing cash flow-$10.12M-$213.09M-$11.97M-$12.37M-$14.19M
Financing cash flow-$40.60M$9.55M-$14.24M-$30.09M-$181.41M
Depreciation & amortization$32.56M$14.54M$12.70M$13.39M$13.04M
Stock-based compensation$13.83M$14.56M$14.60M$13.33M$14.30M
Share buybacks$27.51M$9.44M$11.60M$25.38M$177.84M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.